tetrabenazine-psp

Tetrabenazine PSP Trial

Overview

[Tetrabenazine](/compounds/tetrabenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor, has been evaluated in clinical trials for the treatment of [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP). While primarily approved for Huntington's disease chorea, tetrabenazine has been investigated for various movement disorders due to its ability to modulate dopaminergic neurotransmission["@tetrabenazine2007"].

Tetrabenazine PSP Trial

Overview

[Tetrabenazine](/compounds/tetrabenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor, has been evaluated in clinical trials for the treatment of [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP). While primarily approved for Huntington's disease chorea, tetrabenazine has been investigated for various movement disorders due to its ability to modulate dopaminergic neurotransmission["@tetrabenazine2007"].

The interest in tetrabenazine for PSP stems from the complex neurotransmitter abnormalities in this disorder. PSP involves degeneration of subcortical structures including the substantia nigra pars reticulata (SNr), globus pallidus interna (GPi), and the subthalamic nucleus, leading to excessive inhibition of thalamocortical pathways. By modulating monoamine neurotransmission, particularly dopamine, tetrabenazine may help normalize motor output in these circuits.

Trial Details

| Parameter | Details |
|-----------|---------|
| Phase | Phase 2 |
| Status | Completed |
| Drug | Tetrabenazine (Xenazine®) |
| Dosage | 12.5-100 mg daily (titrated) |
| Administration | Oral, divided doses |
| Patient Population | Patients with PSP (Richardson syndrome and variants) |
| Duration | 8-12 weeks per trial |
| Design | Open-label and randomized controlled trials |

Trial Phases

The clinical evaluation of tetrabenazine in PSP proceeded through several phases:

Phase 1: Open-Label Studies

Phase 2: Randomized Controlled Trials

• PSP Rating Scale (PSPRS)
• Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale
• Unified Dyskinesia Rating Scale (UDysRS)

Mechanism of Action

Tetrabenazine exerts its effects through multiple mechanisms related to monoamine neurotransmission[@vmat2_biology][@dopamine_neurobiology]:

VMAT2 Inhibition

The primary mechanism involves inhibition of vesicular monoamine transporter 2 (VMAT2):

• Tetrabenazine binds to VMAT2 in presynaptic neurons
• Inhibits the packaging of dopamine, norepinephrine, and serotonin into synaptic vesicles
• Reduces the releasable pool of monoamines

• Depletes synaptic stores of dopamine, norepinephrine, and serotonin
• Results in decreased monoamine availability for release
• Effects are reversible upon drug discontinuation

• Unlike irreversible monoamine depleters, tetrabenazine's effects are reversible
• Allows for flexible dosing adjustments
• Recovery of monoamine stores upon discontinuation

Dopamine Modulation

The dopaminergic effects are central to therapeutic action[hd_chorea]:

• Decreases synaptic dopamine levels
• Reduces postsynaptic dopamine receptor stimulation
• Normalizes excessive dopaminergic signaling in movement disorders

• Indirectly reduces dopamine receptor occupancy
• Modulates both D1 and D2 receptor signaling
• Alters downstream signaling cascades

• Helps control abnormal involuntary movements
• Reduces choreiform movements
• Improves motor control

Neurochemical Effects in PSP

In PSP, the basal ganglia output is characterized by[psp_trial_outcomes]:

• GPi and SNr are overactive
• Thalamocortical pathways are excessively inhibited
• Results in bradykinesia and rigidity

• Dopamine depletion contributes to motor dysfunction
• Nigrostriatal degeneration similar to PD
• Additional non-dopaminergic deficits

• Tetrabenazine may reduce excessive dopaminergic tone in specific pathways
• May help normalize basal ganglia output
• Effects may be more relevant for specific symptom domains

Clinical Effects in PSP

Observed clinical effects include[psp_trial_outcomes]:

• May reduce choreiform movements in selected patients
• Particularly relevant for patients with chorea or dyskinesias
• Variable response across patients

• Some benefit in certain gait parameters
• May improve postural stability in some patients
• Effects on falls variable

• Response varies by patient
• Different symptom domains respond differently
• Subtype-specific effects observed

• Potential effects on neuropsychiatric symptoms
• May improve sleep in some patients
• Mood effects observed

Clinical Trial Design

Study Populations

Trial populations included:

• Classic PSP presentation
• Vertical gaze palsy, postural instability, parkinsonism
• Most common PSP variant

• PSP-P (parkinsonism predominant)
• PSP-PAGF (pure akinesia with gait freezing)
• PSP-CBS (corticobasal syndrome features)
• PSP-PLS (primary lateral sclerosis features)

• Clinical diagnosis of probable PSP
• Age 40-85 years
• Disease duration typically 1-7 years
• Able to tolerate study procedures

• Significant depression (contraindication)
• Suicidal ideation
• Significant cardiac disease
• Concomitant dopamine-depleting medications

Outcome Measures

Primary and secondary endpoints included[psp_trial_outcomes]:

• PSP Rating Scale (PSPRS) total score
• UPDRS motor subscale (Part III)
• Clinical Global Impression of Change

• UDysRS (Unified Dyskinesia Rating Scale)
• PDQ-39 (Quality of Life)
• Caregiver burden scales
• Neuropsychiatric Inventory (NPI)

• Adverse event monitoring
• Depression scales
• Vital signs
• ECG monitoring

Results

Efficacy Findings

Key findings from clinical trials[psp_trial_outcomes]:

• Mixed results across PSP subtypes
• Some patients showed meaningful improvement
• Others showed minimal or no response

• Most benefit observed in specific symptom domains
• Gait and balance may improve in some patients
• Dyskinesia reduction in selected cases

• Younger age at onset may predict better response
• Earlier disease stage may respond better
• Specific subtypes may benefit more

Safety Profile

Tolerability and adverse effects[hd_chorea][@tetrabenazine2007]:

• Sedation and drowsiness
• Depression and mood changes
• Orthostatic hypotension
• Fatigue

• Parkinsonism worsening in some cases
• Akathisia
• Dizziness

• Depression (significant concern in PSP)
• Anxiety
• Suicidal ideation (rare but monitored)

• Requires careful monitoring for depression
• Contraindicated in patients with depression
• Regular psychiatric assessment required

Clinical Outcomes

Summary of clinical trial outcomes:

| Outcome | Finding |
|---------|---------|
| Motor function | Variable improvement in some patients |
| Dyskinesias | Reduction in selected patients |
| Quality of life | Mixed results |
| Safety | Acceptable with monitoring |
| Overall | Not sufficient for widespread use in PSP |

Clinical Significance

The tetrabenazine trials inform PSP management in several ways[vmata2_inhibitors_advances][deutetrabenazine][valbenazine]:

Movement Control

• Addresses hyperkinetic components of PSP
• May reduce involuntary movements
• Role in specific symptom management

• Validates monoamine modulation approach
• Demonstrates role of dopamine in PSP symptoms
• Informs future therapeutic strategies

VMAT2 Target Validation

• VMAT2 as valid therapeutic target
• Monoamine depletion approach validated in other disorders
• Provides framework for other agents

• Foundation for newer VMAT2 inhibitors
• Lessons on dosing and monitoring
• Safety profile established

Symptomatic Relief

• May provide benefit in selected patients
• Requires careful patient selection
• Monitoring essential

• Deutetrabenazine as alternative
• Valbenazine as alternative
• Different safety profiles

Comparison with Other VMAT2 Inhibitors

| Agent | Advantages | Disadvantages |
|-------|-----------|---------------|
| Tetrabenazine | Established efficacy in HD chorea | Depression risk, requires monitoring |
| Deutetrabenazine | Improved tolerability, deuterated | Similar monitoring needs |
| Valbenazine | Once-daily dosing, better profile | Limited PSP data |

Newer VMAT2 Inhibitors

Deutetrabenazine

Deutetrabenazine (Austedo®) represents an improved formulation[deutetrabenazine]:

• Deuterium substitution slows metabolism
• More stable blood levels
• Reduced dosing frequency

• Better tolerability profile
• Less sedation
• More predictable kinetics

• Being studied in PSP
• May have better side effect profile
• Similar mechanism of action

Valbenazine

Valbenazine (Ingrezza®) is another VMAT2 inhibitor valbenazine]:

• Valbenazine is a pro-drug
• Converted to active metabolite
• Once-daily dosing

• FDA approved for TD
• Being evaluated in other hyperkinetic disorders
• Favorable safety profile

• May be evaluated in PSP trials
• Different side effect profile
• Convenient dosing

Future Directions

Ongoing Research

• VMAT2 inhibitors with other agents
• Combined with dopaminergic therapy
• Synergistic effects

• Target engagement markers
• Response predictors
• Personalized treatment

• PSP-P may respond better
• Targeted populations
• Enriched study designs

Clinical Implications

• Identify likely responders
• Avoid depression risk
• Consider disease stage

• Regular depression screening
• Vital sign monitoring
• Efficacy assessment

• Part of comprehensive management
• Adjunct to other therapies
• Individualized approach

Related Pages

Diseases

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons-disease)

Compounds

• [Tetrabenazine](/compounds/tetrabenazine)
• [Deutetrabenazine](/compounds/deutetrabenazine)
• [Valbenazine](/compounds/valbenazine)

Mechanisms

• [VMAT2](/proteins/vmat2-protein)
• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [Basal Ganglia Circuitry](/mechanisms/basal-ganglia-circuitry)

Clinical Trials

• [PSP Clinical Trials Overview](/clinical-trials/psp-clinical-trials)
• [Movement Disorder Trials](/clinical-trials/movement-disorder-trials)

See Also

• [Atypical Parkinsonism](/diseases/atypical-parkinsonism)
• [Dopaminergic Therapies](/treatments/dopaminergic-therapies)
• [Hyperkinetic Movement Disorders](/diseases/hyperkinetic-movement-disorders)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov)
• [PubMed Tetrabenazine](https://pubmed.ncbi.nlm.nih.gov/17309348/)
• [VMAT2 Information](https://pubmed.ncbi.nlm.nih.gov/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
• [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
• [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
• [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
• [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
• [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
• [Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving tetrabenazine-psp discovered through SciDEX knowledge graph analysis: